Review Article
Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?
Table 1
Updated phase III randomised trials on dose escalation for prostate cancer. All results are statistically significant, except those marked with n.s.
| | | Median FU (yrs) | Dose (Gy) | Benefit bDFS (%) | Toxicity GI (%) | Toxicity GU (%) |
| MD Anderson | | | | | | | Kuban et al. 2008 | 301 | 8.7 | 70 versus 78 | 59 versus 78 | 13 versus 26 | 13 versus 8 | MGH | | | | | | | Michalski et al. 2015 | 1499 | 7 | 70.2 versus 79.2 | 57 versus 74 | 16 versus 22 | 10 versus 15 | Dutch trial | | | | | | | Heemsbergen et al. 2014 | 669 | 9.1 | 68 versus 78 | 61 versus 69 | 25 versus 35 | 40 versus 41 | Royal Masden | | | | | | | Dearnaley et al. 2014 | 843 | 10 | 64 versus 74 | 43 versus 55 | 24 versus 33 | 8 versus 11 | GETUG | | | | | | | Beckendorf et al. 2011 | 306 | 5.1 | 70 versus 80 | 68 versus 76.5 | 14 versus 19.5 | 10 versus 17.5 |
|
|
bDFS: biochemical disease-free survival. n.s.: not significant.
|